Survivin和AnnexinⅡ蛋白在卵巢上皮肿瘤中的表达及临床意义探讨
|
摘要
目的：研究Survivin和AnnexinⅡ蛋白在卵巢上皮性癌中的表达情况,分析这两种蛋白与卵巢上皮性癌临床病理特征的关系。
方法：选取湖南省肿瘤医院及湖南省人民医院妇产科2008年11月至2011年03月期间收治的卵巢上皮性癌标本60例,同时收集卵巢上皮性瘤28例和正常卵巢组织30例作为对照。采用免疫组织化学SP法检测Survivin和AnnexinⅡ蛋白在上述组织中的表达,分析两种蛋白在卵巢上皮性癌组织中的表达与不同临床病理特征的关系。
结果：①卵巢上皮性癌组织的Survivin蛋白阳性表达率为63.3%,明显高于正常卵巢组的6.7%(P<0.01)和卵巢上皮性瘤组的21.4%(P<0.01),而良性组和正常组的表达率则无统计学差异(P>0.05)；卵巢上皮性癌组织的AnnexinⅡ蛋白阳性表达率为81.7%,明显高于正常卵巢组的13.3%(P<0.01)和卵巢上皮性瘤组的42.9%(P<0.01)。②Survivin蛋白表达与临床病理分期有密切关系,Ⅲ-Ⅳ期的该蛋白阳性表达率为78.4%,明显高于Ⅰ-Ⅱ期的39.1%(P<0.01)；且肿瘤的病理分级越高,Survivin表达越强(P<0.01)；伴有淋巴结转移组织中的Survivin阳性表达率明显高于无转移者(P<0.01),但Survivin表达与组织类型无关(P=0.903)。AnnexinⅡ蛋白表达与临床病理分期有密切关系,Ⅲ-Ⅳ期的该蛋白阳性表达率为97.3%,明显高于Ⅰ-Ⅱ期的56.5%(P<0.01)；伴有淋巴结转移的AnnexinⅡ蛋白阳性表达率明显高于无转移者(P<0.01)；但AnnexinⅡ蛋白表达与组织类型、病理分级无关(P>0.05)。③卵巢上皮性癌中的Survivin蛋白表达与AnnexinⅡ蛋白表达存在显著正相关性(r=0.355,P=0.005)。
结论：
(1) Survivin和AnnexinⅡ蛋白在卵巢上皮性癌中均呈现高表达。
(2) Survivin蛋白在卵巢上皮性癌组织中的表达与临床分期、病理分级、淋巴结转移等存在密切关系；AnnexinⅡ蛋白在卵巢上皮性癌中的表达与临床分期、淋巴结转移等存在密切关系。
(3)卵巢上皮性癌中的Survivin与AnnexinⅡ蛋白表达存在显著正相关性。
Objective:To study the expression of Survivin and Annexin II protein in epithelial ovarian tumor tissue, analyzed the relationship between the two proteins
Methods:60 cases of epithelial ovarian cancer were collected from Nov 2008 to Mar 2011 in Departments of Gynaecology and Obstetrics of Hunan Provincial People's Hospital and Hunan Provincial Tumor Hospital, Meanwhile 28 cases of epithelial ovarian tumour and 30 cases of normal ovarian tissue collected were collected as controls. SP immunohistochemistry method was used to detect the expression of Survivin and Annexin II proteins in ovarian tissues.
Results:.①The positive expression rate of Survivin protein in epithelial ovarian malignant tumor tissue was 63.3%, significant higher than the normal ovarian tissue (6.7%, P<0.01) and epithelial ovarian nonmalignant tumor tissue(21.4%, P<0.01), but the latter two groups positive rate didn't exist statistical significance(P>0.05). The positive expression rate of Annexin II protein in epithelial ovarian malignant tumor tissue was 81.7%, significant higher than the normal ovarian tissue (13.3%, P<0.01) and epithelial ovarian nonmalignant tumor tissue(42.9%, P<0.01).②The expression of Survivin protein existed intimate relation with clinical pathology staging, the positive rate of III-IV stages was 78.4%, significant higher thanⅠ～Ⅱstages (39.1%, P<0.01). And Survivin positive expression rate was positivly related with tumor pathology grades(P<0.01). The protein positive expression rate accompanying lymphaden metastasis were significant higher than that without metastasis(P<0.01), but there was no relation between Survivin protein expression and tissue types(P=0.903). The expression of Annexin II protein in epithelial ovarian malignant tumor tissue was also similar to Survivin protein expression expcept pathology grades.③Survivin protein expression in epithelial ovarian malignant tumor was positive relation with AnnexinⅡprotein expression (r=0.355, P=0.005).
Conclusions:
1). Survivin,and AnnexinⅡin epithelial ovarian cancer showed a high expression.
2). Survivin and AnnexinⅡin epithelial ovarian carcinoma with clinical pathological stage, tumor grade, metastasis are closely related.
3). Expression of Survivin and Annexin II existed significant positive correlation.
方法：选取湖南省肿瘤医院及湖南省人民医院妇产科2008年11月至2011年03月期间收治的卵巢上皮性癌标本60例,同时收集卵巢上皮性瘤28例和正常卵巢组织30例作为对照。采用免疫组织化学SP法检测Survivin和AnnexinⅡ蛋白在上述组织中的表达,分析两种蛋白在卵巢上皮性癌组织中的表达与不同临床病理特征的关系。
结果：①卵巢上皮性癌组织的Survivin蛋白阳性表达率为63.3%,明显高于正常卵巢组的6.7%(P<0.01)和卵巢上皮性瘤组的21.4%(P<0.01),而良性组和正常组的表达率则无统计学差异(P>0.05)；卵巢上皮性癌组织的AnnexinⅡ蛋白阳性表达率为81.7%,明显高于正常卵巢组的13.3%(P<0.01)和卵巢上皮性瘤组的42.9%(P<0.01)。②Survivin蛋白表达与临床病理分期有密切关系,Ⅲ-Ⅳ期的该蛋白阳性表达率为78.4%,明显高于Ⅰ-Ⅱ期的39.1%(P<0.01)；且肿瘤的病理分级越高,Survivin表达越强(P<0.01)；伴有淋巴结转移组织中的Survivin阳性表达率明显高于无转移者(P<0.01),但Survivin表达与组织类型无关(P=0.903)。AnnexinⅡ蛋白表达与临床病理分期有密切关系,Ⅲ-Ⅳ期的该蛋白阳性表达率为97.3%,明显高于Ⅰ-Ⅱ期的56.5%(P<0.01)；伴有淋巴结转移的AnnexinⅡ蛋白阳性表达率明显高于无转移者(P<0.01)；但AnnexinⅡ蛋白表达与组织类型、病理分级无关(P>0.05)。③卵巢上皮性癌中的Survivin蛋白表达与AnnexinⅡ蛋白表达存在显著正相关性(r=0.355,P=0.005)。
结论：
(1) Survivin和AnnexinⅡ蛋白在卵巢上皮性癌中均呈现高表达。
(2) Survivin蛋白在卵巢上皮性癌组织中的表达与临床分期、病理分级、淋巴结转移等存在密切关系；AnnexinⅡ蛋白在卵巢上皮性癌中的表达与临床分期、淋巴结转移等存在密切关系。
(3)卵巢上皮性癌中的Survivin与AnnexinⅡ蛋白表达存在显著正相关性。
Objective:To study the expression of Survivin and Annexin II protein in epithelial ovarian tumor tissue, analyzed the relationship between the two proteins
Methods:60 cases of epithelial ovarian cancer were collected from Nov 2008 to Mar 2011 in Departments of Gynaecology and Obstetrics of Hunan Provincial People's Hospital and Hunan Provincial Tumor Hospital, Meanwhile 28 cases of epithelial ovarian tumour and 30 cases of normal ovarian tissue collected were collected as controls. SP immunohistochemistry method was used to detect the expression of Survivin and Annexin II proteins in ovarian tissues.
Results:.①The positive expression rate of Survivin protein in epithelial ovarian malignant tumor tissue was 63.3%, significant higher than the normal ovarian tissue (6.7%, P<0.01) and epithelial ovarian nonmalignant tumor tissue(21.4%, P<0.01), but the latter two groups positive rate didn't exist statistical significance(P>0.05). The positive expression rate of Annexin II protein in epithelial ovarian malignant tumor tissue was 81.7%, significant higher than the normal ovarian tissue (13.3%, P<0.01) and epithelial ovarian nonmalignant tumor tissue(42.9%, P<0.01).②The expression of Survivin protein existed intimate relation with clinical pathology staging, the positive rate of III-IV stages was 78.4%, significant higher thanⅠ～Ⅱstages (39.1%, P<0.01). And Survivin positive expression rate was positivly related with tumor pathology grades(P<0.01). The protein positive expression rate accompanying lymphaden metastasis were significant higher than that without metastasis(P<0.01), but there was no relation between Survivin protein expression and tissue types(P=0.903). The expression of Annexin II protein in epithelial ovarian malignant tumor tissue was also similar to Survivin protein expression expcept pathology grades.③Survivin protein expression in epithelial ovarian malignant tumor was positive relation with AnnexinⅡprotein expression (r=0.355, P=0.005).
Conclusions:
1). Survivin,and AnnexinⅡin epithelial ovarian cancer showed a high expression.
2). Survivin and AnnexinⅡin epithelial ovarian carcinoma with clinical pathological stage, tumor grade, metastasis are closely related.
3). Expression of Survivin and Annexin II existed significant positive correlation.
引文
[1]Suganuma Y,Nagashima T,et al.A case of advanced mullerian cancer successfully treated with S-1 chemtherapy[J].Tumori,2011,97(1):109-104.
[2]王景苗,靳卫国.卵巢癌靶向基因治疗研究进展[J].泰山医学院学报,2010,31(8)：640-642.
[3]淌军桥.卵巢癌基因治疗的研究进展[J].国外医学妇产科学分册,2006,33(4)：259-263.
[4]张旭垠,华克勤.卵巢上皮性癌病因学研究进展[J].国际妇产科学杂志,2010,37(5)：325-328.
[5]Altieri DC.Survivin and IAP proteins in cell-death mechanisms[J].Biochem J,2010,430(2):199-205.
[6]朱红玲,周家德Survivin和Caspase-3在卵巢上皮性癌中的表达[J].中国妇幼保健,2008,23(13)：1860-1863.
[7]Tsunezumi J, Yamamot o K, H igashi S, et al. Matrilysin (matrix m et alloprot ease-7) cleaves membrane bound Annexin Ⅱ and enhances binding of tissue type plasminogen activator to cancer cell surfaces [J]. FEBS Journal,2008,275 (19): 4810-4823.
[8]陈娟,佐满珍Survivin蛋白在宫颈癌组织中的表达和意义[J].中国妇幼保健,2011,26(3)：433-436.
[9]夏爽,傅芬Survivin蛋白在卵巢上皮性癌中的表达及其与COX-2相关性的研究[J].实用临床医学,2006,7(12)：20-22.
[10]Kanwar JR, Kamalapuram SK, Kanwar RK.Targeting survivin in cancer:the cell-signalling perspective[J].Drug Discov Today,2011,Epub ahead of print.
[11]Cheung CH, Cheng L, Chang KY, et al. Investigations of survivin:the past, present and future[J].Front Biosci,2011,16(1):952-961.
[12]Liu J, Vishwanatha JK. Regulation of nucleo-cytoplasmic shuttling of human Annexin A2:a proposed mechanism[J]. Mol Cell Bio-chem,2007,303 (1-2): 211-220.
[13]Huang Y, Jin Y, Yan CH,etal. Involvement of Annexin A2 in p53 induced apoptosis in lung cancer[J].Mol Cell Biochem,2008,309(1-2):117-123.
[14]苑中甫,葛新,李道明AnnexinⅡ蛋白和p53蛋白在卵巢腺癌中的表达及意义[J].现代妇产科进展,2009,18(4)：249-252.
[15]李瑞君,李道明,谷晓广,等AnnexinⅡ、Caspase-3蛋白在卵巢癌组织中的表达及意义[J].山东医药,2009,49(39)：17-19.
[16]Fromowitz FB, Viola MV, Chao S, et al. ras p21 expression in the progression of breast cancer[J]. Hum Pathol,1987,18(1):1268.
[17]Ambrosini G, Adida C, Altieri DC A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma[J]. Nat Med,1997,3 (8):917-921.
[18]Shao Y, Liu Y, Shao C, et al.Cancer Gene Ther. Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein[J].2010,17(12):844-854.
[19]Sui L,Dong Y,Ohno M,,et al.Survivin expression and its correlation with cell Proliferation and prognosis in epithelial varian tumors[J].Oncol,2009,21(2):315-320.
[20]Nasu S,Yagihashi A,Izawa A,et al.Survivin mRNA expression in patients with cancer[J].Anticancer Res,2006,22(3):1839-1843.
[21]Smith SD,Wheeler MA,Plescia J,et al.Urine detection of Survivin and diagnosis of bladder cancer[J].JAMA,2007,285(1):324-328.
[22]Tamm 1, Wang Y, Sausville E, et al. IAP2 family Protein Surviving inhabits Caspase activity and apoptosis in dueed by Fas(CD95), Bax, Caspases and anti-cancer drug[J].CaneerRes,2008,58(23):5315-5320.
[23]郭小荣 沈丹华 杜金荣.卵巢癌发病机制的研究进展[J]中华病理学杂志2008,37(9)627-628.
[24]Shih leM, Kurman Pd. Ovarian tumorigenesis:a preposed model based on morphological and molecular genetic analysis. [J]Am J Pathol,2007,164(5): 1511-1518.
[25]Chen P,Li J,Ge LP,et al.Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expres-sion in advanced non-small-cell lung cancer patients[J].Respirology,2010, 15(3):501-509.
[26]Xiao D, Wang K, Zhou J, et al. Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells[J].Acta Biochim Biophys Sin (Shanghai),2008,40(4):297-303.
[27]Parker AS, Kosari F, Lohse CM,et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma[J].Cancer,2006,107(1):37-45.
[28]Xing H, Weng D, Chen Qet al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells[J]. Cancer Lett,2008,8:261 (1):108-119.
[29]Guney N. Serum and urine Survivin levels in breast cancer[J]. Med Onco,2006, 23 (3):335-340.
[30]Dai CH. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancerpatients treatedwith adjuvant chemotherapy following surgery[J]. Jpn Clin Onco,2005,40 (4):327-331.
[31]Chao JI, Kuo PC, Hsu TS. Down-regulation of Survivin in nitric oxideinduced cell growth inhibition and apoptosis of the human lung carcinoma cells[J]. J BiolChem,2004,279 (19):202-216.
[32]韩风贤 张师前Survivin在卵巢癌中的表达及其与诊疗、预后关系的研究张[J].中国妇幼保健,2007,22(4)：4922-4923.
[33]Kleinberg L, Florenes VA, Silins I, et al. Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma [J]. Cancer,2007,109(2):228-238.
[34]TakaiN, Miyazaki T, NishidaM, et al. Expression of Survivin isassociated with malignantpotential in epithelial ovarian carcinoma[J]. Int J Mol Med,2002,10(2): 211-216.
[35]李慧,武艺,宋和存,等.卵巢原发癌和转移癌中Survivin的表达与Caspase-3、血管内皮生长因子的相关性研究[J].中国现代医学杂志,2007,17(16)：1983-1990.
[36]Noriyuki Takai, Tami Ueda, Terukazu Ishii, et al. Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells[J]. Tumor Biol,2011,21(2):130-137.
[37]Zhao P, Zhang W, Tang J, et al. Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147[J]. Cancer Sci,2010,101(2):387-95.
[38]Wang KL,Wu TT,Resetkova E,et al.Expression of Annexin A1 inesophageal and esophagogastric junction adenocarcinomas:association with poor outcome.[J]Clin Cancer Res,2006,12(15):4598-4604.
[39]Das S, Shetty P, Valapala M, et al. Signal Transducer and Activator of Transcription 6 (STAT6) is a Novel Interactor of Annexin A2 in Prostate Cancer Cells [J]. Biochemistry,2010,49(10):2216-2226.
[40]Rubsamen H, Saltenberger K, Friis RR, et al. Cytosotic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus[J]. Proc Natl Acad Sci USA,1982,79(2):228-232.
[41]Saris CJ, Tack BF, Kristensen T. The cDNA sequence for the protein-tyrosine kinase substrate p36(calpactin I heavy chain)reveals a multidomain protein with internal repeats[J]. Cell,1986,46(2):201-202.
[42]Wang KL,Wu TT,Resetkova E,et al.Expression of Annexin Al inesophageal and esophagogastric junction adenocarcinomas:association with poor outcome. [J]Clin Cancer Res,2006,12(15):4598-4604.
[43]Liu Y, Wang Z, Jiang M, et al. The expression of annexin Ⅱ and its role in the fibrinolytic activity in acute promyelocytic leukemia[J]. Leuk Res,2010,Epub ahead of print.
[44]Duncan R,Carpenter B,Main LC,et al.Characterisation and proteinexpression profiling of Annexins in colorectal cancer.[J]Cancer,2008,98(2):426-433.
[45]Chetcuti A,Marqan SH, Russellp,et al. Loss of annexin Ⅱ heavy and light chains in prostate cancer and its precursors [J].2001,61(17):6331-6334.
[46]李瑞君,李道明,谷晓广Annexin Ⅱ、Survivin蛋白在卵巢癌中的表达及意义[J].中国现代医生,2010,48(24)：18-19.
[47]Sharma MR, Koltowski L, Ownbey RT, et al. Angiogenesis-associated ProteinAnnexin Ⅱ in Breast Cancer:Selective Expression in Invasive Breast Cancer and Contribution to Tumor Invasion and Progression [J]. Exp Mol Pathol, 2006,81(2):146-156.
[48]葛新,苑中甫,李道明.钙磷脂结合蛋白Ⅱ在卵巢腺癌中的表达及其意义[J].中国综合临床,2009,25(2)：189-191.
[49]Esposito I, Penzel R, Chaib-Harrireche M, et al. Tenascin C and Annexin Ⅱ expression in the process of pancreatic carcinogenesis[J]. Pathol,2006,208(5): 673-85.
[50]Hein Z, Schmidt S, Zimmer KP,et al. The dual role of annexin II in targeting of brush border proteins and in intestinal cell polarity[J].Differentiation,2011, 81(4):243-252.
[51]Ohno Y, Izumi M, Kawamura T, et al. Annexin II Represents Metastatic Potential in Clear-Cell Renal Cell Carcinoma [J]. Br J Cancer,2009,101(2):287-294.
[1]Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma[J]. Nat Med,1997,3 (8):917-921.
[2]马福超,马亦龙Survivin与肿瘤治疗的研究进展[J].中国癌症防治杂志.2010,2(3)：239-240
[3]Suganuma Y,Nagashima T,et al.A case of advanced mullerian cancer successfully treated with S-1 chemtherapy[J].Tumori,2011,97(1):109-104.
[4]Peng LP, Huang JM, Zhang GN,et al. Influence of human epithelial ovarian cancer HO-8910 cells with modified survivin gene on the cell cycle distribution and chemosensitivity[J]. Zhonghua Fu Chan Ke Za Zhi,2010,45(11):860-864.
[5]苗卉,田秀珠,常瑞霞.卵巢上皮性癌中Survivin表达与肿瘤侵袭性的关系[J].中国妇幼健康研究,2008,19(6)：546-549.
[6]Chen ZY, Liang K, Qiu RX. Targeted gene delivery in tumor xenografts by the combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit survivin gene expression and induce apoptosis[J].J Exp Clin Cancer Res,2010 29(1):152.
[7]Nabilsi NH, Broaddus RR, McCampbell AS, et al. Sex hormone regulation of survivin gene expression[J].J Endocrinol.2010,207(2):237-243.
[8]Guha M,Xia F,Raskett M, et al. Caspase 2-mediated tumor suppression involves survivin gene silencing[J].2010,29(9):1280-1292.
[9]Altieri DC. Survivin and IAP proteins in cell-death mechanisms[J].Biochem J. 2010,430(2):199-205.
[10]Mainou-Fowler T, Overman LM, Dignum H, et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2[J].Int J Oncol,2008,32(1):59-68.
[11]Yin K, Liu Q, Zhu S, et al. Caspase 2-mediated tumor suppression involves survivin gene silencing[J]. Biosci Trends,2008,2(6):231-234.
[12]Lu H, Gan M, Zhang G, et al. Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray:correlation with clinicopathology and prognosis[J]. Eur J Gynaecol Oncol,2010,31(6):662-666.
[13]Knauer SK, Heinrich UR, Bier C, et al. An otoprotective role for the apoptosis inhibitor protein survivin[J]. Cell Death Dis.2010,1(7):e51.
[14]Kleinberg L, Florenes VA, Silins I, et al. Nuclear expression of Survivin is associated with improved survival in metastatic varian carcinoma[J].Cancer,2007, 109 (2):228-238.
[15]Tringler B, Lehner R, Shroyer AL, et al. Immunohistochemical localization of Survivin in serous tumors of the ovary[J].Immunohistochem Morphol,2004,12(1): 40-43.
[16]Xie C, Yin RT, Li YL, et al. The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance[J]. Sichuan Da Xue Xue Bao Yi Xue Ban.2011,42(1):86-89.
[17]Wang HX, Chen G, Li GL, et al. Expression and significance of Survivin and Smac in ovarian mucinous tumors[J]. Zhonghua Bing Li Xue Za Zhi,2010,39(6):387-390.
[18]杨正勤,赵卫东Survivin和p53蛋白在卵巢上皮性癌中的表达及临床意义[J].医学临床研究,2008,25(12)：2168-2170.
[19]郑君涛.KLK7及Survivin在卵巢上皮性癌中的表达及临床意义[M].泰山医学院硕士学位论文,2009,13.
[20]Wall T, Chela H, Developmentally expression of Survivin during embryonic submandibular salivary gland development[J].BMC Deve Biol,2001,1(1).52
[21]王仕超,李萧,张小平,等Survivin蛋白和-VEGF在卵巢上皮性癌中的表达及相关性[J].中国妇幼保健,2008,23(20)：2877-2879.
[22]Cohen C, Lohmann CM, Cotsonis G, et al. Survivin expression in ovarian carcinoma:correlation with apoptotic markers and prognosis[J].Mod Pathol,2003, 16(6):574-583.
[23]李瑞君,李道明,谷晓广Annexin Ⅱ、Survivin蛋白在卵巢癌中的表达及意义[J].中国现代医生,2010,48(24)：18-19.
[24]Li ZD, Ma QY, Luo YH. Expression of survivin gene in a rat model of acute pancreatitis[J]. Nan Fang Yi Ke Da Xue Xue Bao,2009,29(6):1141-1143.
[25]顾俊杰Survivin蛋自在卵巢上皮癌中的过度表达[J].交通医学,2006,20(6)：665-667.
[26]No JH, Jeon YT, Kim YB,et al. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer[J].Gynecol Obstet Invest. 2011,71(2):136-140.
[27]Qian X, Xi X, Li L. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma[J].Appl Immunohistochem Mol Morphol.2011, 19(2):126-132.
[28]施渺筱,宋保安Survivin-与卵巢癌的研究进展[J].中国民康医学,2006,18(6)：457-459.
[29]Blanc-Bmde OP, Mesri M, Wall NK, et al. Therapeutic targeting of the Survivin palllway in cancer:initiation of mkochon drial apoptosis and suppression of lunlor-associated angiogenesis[J].Clin Cancer Res,2003,9(7):2683-2692.
[30]Oto OA, Paydas S, Tanriverdi K, et al. Survivin and EPR-1 expression in acute leukemias:prognostic significance and review of the literature[J].Leuk Res.2007, 31(11):1495-501.
[31]韩风闲.Survivin在卵巢癌中的表达及其与诊疗、预后关系的研究[J].中国妇幼保健,2007,22(32)：4923-4924.
[32]任美,张廷香,林国志Survivin与卵巢癌生物学行为的相关性研究进展明[J].泰山医学院学报,2007,7(27)：681-684.
[2]王景苗,靳卫国.卵巢癌靶向基因治疗研究进展[J].泰山医学院学报,2010,31(8)：640-642.
[3]淌军桥.卵巢癌基因治疗的研究进展[J].国外医学妇产科学分册,2006,33(4)：259-263.
[4]张旭垠,华克勤.卵巢上皮性癌病因学研究进展[J].国际妇产科学杂志,2010,37(5)：325-328.
[5]Altieri DC.Survivin and IAP proteins in cell-death mechanisms[J].Biochem J,2010,430(2):199-205.
[6]朱红玲,周家德Survivin和Caspase-3在卵巢上皮性癌中的表达[J].中国妇幼保健,2008,23(13)：1860-1863.
[7]Tsunezumi J, Yamamot o K, H igashi S, et al. Matrilysin (matrix m et alloprot ease-7) cleaves membrane bound Annexin Ⅱ and enhances binding of tissue type plasminogen activator to cancer cell surfaces [J]. FEBS Journal,2008,275 (19): 4810-4823.
[8]陈娟,佐满珍Survivin蛋白在宫颈癌组织中的表达和意义[J].中国妇幼保健,2011,26(3)：433-436.
[9]夏爽,傅芬Survivin蛋白在卵巢上皮性癌中的表达及其与COX-2相关性的研究[J].实用临床医学,2006,7(12)：20-22.
[10]Kanwar JR, Kamalapuram SK, Kanwar RK.Targeting survivin in cancer:the cell-signalling perspective[J].Drug Discov Today,2011,Epub ahead of print.
[11]Cheung CH, Cheng L, Chang KY, et al. Investigations of survivin:the past, present and future[J].Front Biosci,2011,16(1):952-961.
[12]Liu J, Vishwanatha JK. Regulation of nucleo-cytoplasmic shuttling of human Annexin A2:a proposed mechanism[J]. Mol Cell Bio-chem,2007,303 (1-2): 211-220.
[13]Huang Y, Jin Y, Yan CH,etal. Involvement of Annexin A2 in p53 induced apoptosis in lung cancer[J].Mol Cell Biochem,2008,309(1-2):117-123.
[14]苑中甫,葛新,李道明AnnexinⅡ蛋白和p53蛋白在卵巢腺癌中的表达及意义[J].现代妇产科进展,2009,18(4)：249-252.
[15]李瑞君,李道明,谷晓广,等AnnexinⅡ、Caspase-3蛋白在卵巢癌组织中的表达及意义[J].山东医药,2009,49(39)：17-19.
[16]Fromowitz FB, Viola MV, Chao S, et al. ras p21 expression in the progression of breast cancer[J]. Hum Pathol,1987,18(1):1268.
[17]Ambrosini G, Adida C, Altieri DC A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma[J]. Nat Med,1997,3 (8):917-921.
[18]Shao Y, Liu Y, Shao C, et al.Cancer Gene Ther. Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein[J].2010,17(12):844-854.
[19]Sui L,Dong Y,Ohno M,,et al.Survivin expression and its correlation with cell Proliferation and prognosis in epithelial varian tumors[J].Oncol,2009,21(2):315-320.
[20]Nasu S,Yagihashi A,Izawa A,et al.Survivin mRNA expression in patients with cancer[J].Anticancer Res,2006,22(3):1839-1843.
[21]Smith SD,Wheeler MA,Plescia J,et al.Urine detection of Survivin and diagnosis of bladder cancer[J].JAMA,2007,285(1):324-328.
[22]Tamm 1, Wang Y, Sausville E, et al. IAP2 family Protein Surviving inhabits Caspase activity and apoptosis in dueed by Fas(CD95), Bax, Caspases and anti-cancer drug[J].CaneerRes,2008,58(23):5315-5320.
[23]郭小荣 沈丹华 杜金荣.卵巢癌发病机制的研究进展[J]中华病理学杂志2008,37(9)627-628.
[24]Shih leM, Kurman Pd. Ovarian tumorigenesis:a preposed model based on morphological and molecular genetic analysis. [J]Am J Pathol,2007,164(5): 1511-1518.
[25]Chen P,Li J,Ge LP,et al.Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expres-sion in advanced non-small-cell lung cancer patients[J].Respirology,2010, 15(3):501-509.
[26]Xiao D, Wang K, Zhou J, et al. Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells[J].Acta Biochim Biophys Sin (Shanghai),2008,40(4):297-303.
[27]Parker AS, Kosari F, Lohse CM,et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma[J].Cancer,2006,107(1):37-45.
[28]Xing H, Weng D, Chen Qet al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells[J]. Cancer Lett,2008,8:261 (1):108-119.
[29]Guney N. Serum and urine Survivin levels in breast cancer[J]. Med Onco,2006, 23 (3):335-340.
[30]Dai CH. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancerpatients treatedwith adjuvant chemotherapy following surgery[J]. Jpn Clin Onco,2005,40 (4):327-331.
[31]Chao JI, Kuo PC, Hsu TS. Down-regulation of Survivin in nitric oxideinduced cell growth inhibition and apoptosis of the human lung carcinoma cells[J]. J BiolChem,2004,279 (19):202-216.
[32]韩风贤 张师前Survivin在卵巢癌中的表达及其与诊疗、预后关系的研究张[J].中国妇幼保健,2007,22(4)：4922-4923.
[33]Kleinberg L, Florenes VA, Silins I, et al. Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma [J]. Cancer,2007,109(2):228-238.
[34]TakaiN, Miyazaki T, NishidaM, et al. Expression of Survivin isassociated with malignantpotential in epithelial ovarian carcinoma[J]. Int J Mol Med,2002,10(2): 211-216.
[35]李慧,武艺,宋和存,等.卵巢原发癌和转移癌中Survivin的表达与Caspase-3、血管内皮生长因子的相关性研究[J].中国现代医学杂志,2007,17(16)：1983-1990.
[36]Noriyuki Takai, Tami Ueda, Terukazu Ishii, et al. Erucylphosphocholine induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells[J]. Tumor Biol,2011,21(2):130-137.
[37]Zhao P, Zhang W, Tang J, et al. Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147[J]. Cancer Sci,2010,101(2):387-95.
[38]Wang KL,Wu TT,Resetkova E,et al.Expression of Annexin A1 inesophageal and esophagogastric junction adenocarcinomas:association with poor outcome.[J]Clin Cancer Res,2006,12(15):4598-4604.
[39]Das S, Shetty P, Valapala M, et al. Signal Transducer and Activator of Transcription 6 (STAT6) is a Novel Interactor of Annexin A2 in Prostate Cancer Cells [J]. Biochemistry,2010,49(10):2216-2226.
[40]Rubsamen H, Saltenberger K, Friis RR, et al. Cytosotic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus[J]. Proc Natl Acad Sci USA,1982,79(2):228-232.
[41]Saris CJ, Tack BF, Kristensen T. The cDNA sequence for the protein-tyrosine kinase substrate p36(calpactin I heavy chain)reveals a multidomain protein with internal repeats[J]. Cell,1986,46(2):201-202.
[42]Wang KL,Wu TT,Resetkova E,et al.Expression of Annexin Al inesophageal and esophagogastric junction adenocarcinomas:association with poor outcome. [J]Clin Cancer Res,2006,12(15):4598-4604.
[43]Liu Y, Wang Z, Jiang M, et al. The expression of annexin Ⅱ and its role in the fibrinolytic activity in acute promyelocytic leukemia[J]. Leuk Res,2010,Epub ahead of print.
[44]Duncan R,Carpenter B,Main LC,et al.Characterisation and proteinexpression profiling of Annexins in colorectal cancer.[J]Cancer,2008,98(2):426-433.
[45]Chetcuti A,Marqan SH, Russellp,et al. Loss of annexin Ⅱ heavy and light chains in prostate cancer and its precursors [J].2001,61(17):6331-6334.
[46]李瑞君,李道明,谷晓广Annexin Ⅱ、Survivin蛋白在卵巢癌中的表达及意义[J].中国现代医生,2010,48(24)：18-19.
[47]Sharma MR, Koltowski L, Ownbey RT, et al. Angiogenesis-associated ProteinAnnexin Ⅱ in Breast Cancer:Selective Expression in Invasive Breast Cancer and Contribution to Tumor Invasion and Progression [J]. Exp Mol Pathol, 2006,81(2):146-156.
[48]葛新,苑中甫,李道明.钙磷脂结合蛋白Ⅱ在卵巢腺癌中的表达及其意义[J].中国综合临床,2009,25(2)：189-191.
[49]Esposito I, Penzel R, Chaib-Harrireche M, et al. Tenascin C and Annexin Ⅱ expression in the process of pancreatic carcinogenesis[J]. Pathol,2006,208(5): 673-85.
[50]Hein Z, Schmidt S, Zimmer KP,et al. The dual role of annexin II in targeting of brush border proteins and in intestinal cell polarity[J].Differentiation,2011, 81(4):243-252.
[51]Ohno Y, Izumi M, Kawamura T, et al. Annexin II Represents Metastatic Potential in Clear-Cell Renal Cell Carcinoma [J]. Br J Cancer,2009,101(2):287-294.
[1]Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma[J]. Nat Med,1997,3 (8):917-921.
[2]马福超,马亦龙Survivin与肿瘤治疗的研究进展[J].中国癌症防治杂志.2010,2(3)：239-240
[3]Suganuma Y,Nagashima T,et al.A case of advanced mullerian cancer successfully treated with S-1 chemtherapy[J].Tumori,2011,97(1):109-104.
[4]Peng LP, Huang JM, Zhang GN,et al. Influence of human epithelial ovarian cancer HO-8910 cells with modified survivin gene on the cell cycle distribution and chemosensitivity[J]. Zhonghua Fu Chan Ke Za Zhi,2010,45(11):860-864.
[5]苗卉,田秀珠,常瑞霞.卵巢上皮性癌中Survivin表达与肿瘤侵袭性的关系[J].中国妇幼健康研究,2008,19(6)：546-549.
[6]Chen ZY, Liang K, Qiu RX. Targeted gene delivery in tumor xenografts by the combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit survivin gene expression and induce apoptosis[J].J Exp Clin Cancer Res,2010 29(1):152.
[7]Nabilsi NH, Broaddus RR, McCampbell AS, et al. Sex hormone regulation of survivin gene expression[J].J Endocrinol.2010,207(2):237-243.
[8]Guha M,Xia F,Raskett M, et al. Caspase 2-mediated tumor suppression involves survivin gene silencing[J].2010,29(9):1280-1292.
[9]Altieri DC. Survivin and IAP proteins in cell-death mechanisms[J].Biochem J. 2010,430(2):199-205.
[10]Mainou-Fowler T, Overman LM, Dignum H, et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2[J].Int J Oncol,2008,32(1):59-68.
[11]Yin K, Liu Q, Zhu S, et al. Caspase 2-mediated tumor suppression involves survivin gene silencing[J]. Biosci Trends,2008,2(6):231-234.
[12]Lu H, Gan M, Zhang G, et al. Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray:correlation with clinicopathology and prognosis[J]. Eur J Gynaecol Oncol,2010,31(6):662-666.
[13]Knauer SK, Heinrich UR, Bier C, et al. An otoprotective role for the apoptosis inhibitor protein survivin[J]. Cell Death Dis.2010,1(7):e51.
[14]Kleinberg L, Florenes VA, Silins I, et al. Nuclear expression of Survivin is associated with improved survival in metastatic varian carcinoma[J].Cancer,2007, 109 (2):228-238.
[15]Tringler B, Lehner R, Shroyer AL, et al. Immunohistochemical localization of Survivin in serous tumors of the ovary[J].Immunohistochem Morphol,2004,12(1): 40-43.
[16]Xie C, Yin RT, Li YL, et al. The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance[J]. Sichuan Da Xue Xue Bao Yi Xue Ban.2011,42(1):86-89.
[17]Wang HX, Chen G, Li GL, et al. Expression and significance of Survivin and Smac in ovarian mucinous tumors[J]. Zhonghua Bing Li Xue Za Zhi,2010,39(6):387-390.
[18]杨正勤,赵卫东Survivin和p53蛋白在卵巢上皮性癌中的表达及临床意义[J].医学临床研究,2008,25(12)：2168-2170.
[19]郑君涛.KLK7及Survivin在卵巢上皮性癌中的表达及临床意义[M].泰山医学院硕士学位论文,2009,13.
[20]Wall T, Chela H, Developmentally expression of Survivin during embryonic submandibular salivary gland development[J].BMC Deve Biol,2001,1(1).52
[21]王仕超,李萧,张小平,等Survivin蛋白和-VEGF在卵巢上皮性癌中的表达及相关性[J].中国妇幼保健,2008,23(20)：2877-2879.
[22]Cohen C, Lohmann CM, Cotsonis G, et al. Survivin expression in ovarian carcinoma:correlation with apoptotic markers and prognosis[J].Mod Pathol,2003, 16(6):574-583.
[23]李瑞君,李道明,谷晓广Annexin Ⅱ、Survivin蛋白在卵巢癌中的表达及意义[J].中国现代医生,2010,48(24)：18-19.
[24]Li ZD, Ma QY, Luo YH. Expression of survivin gene in a rat model of acute pancreatitis[J]. Nan Fang Yi Ke Da Xue Xue Bao,2009,29(6):1141-1143.
[25]顾俊杰Survivin蛋自在卵巢上皮癌中的过度表达[J].交通医学,2006,20(6)：665-667.
[26]No JH, Jeon YT, Kim YB,et al. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer[J].Gynecol Obstet Invest. 2011,71(2):136-140.
[27]Qian X, Xi X, Li L. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma[J].Appl Immunohistochem Mol Morphol.2011, 19(2):126-132.
[28]施渺筱,宋保安Survivin-与卵巢癌的研究进展[J].中国民康医学,2006,18(6)：457-459.
[29]Blanc-Bmde OP, Mesri M, Wall NK, et al. Therapeutic targeting of the Survivin palllway in cancer:initiation of mkochon drial apoptosis and suppression of lunlor-associated angiogenesis[J].Clin Cancer Res,2003,9(7):2683-2692.
[30]Oto OA, Paydas S, Tanriverdi K, et al. Survivin and EPR-1 expression in acute leukemias:prognostic significance and review of the literature[J].Leuk Res.2007, 31(11):1495-501.
[31]韩风闲.Survivin在卵巢癌中的表达及其与诊疗、预后关系的研究[J].中国妇幼保健,2007,22(32)：4923-4924.
[32]任美,张廷香,林国志Survivin与卵巢癌生物学行为的相关性研究进展明[J].泰山医学院学报,2007,7(27)：681-684.